News

Bariatric surgery beats GLP-1s for type 2 diabetes, study finds | STAT

Clinical 72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
July 30, 2026↗ source

A secondary analysis of a long-term clinical trial published in the Annals of Internal Medicine indicates that bariatric surgery outperforms medical therapy, including GLP-1 drugs, for treating type 2 diabetes and obesity across diverse income levels. The research found that surgery led to superior outcomes in blood glucose control, weight loss, and diabetes remission regardless of social determinants of health. While acknowledging the rapid evolution of more potent obesity medications, the authors maintain that metabolic surgery remains an effective and underutilized durable solution.

Related peptides

GLP-1GLP-1sGLP-1 drugs
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.